Instil Bio, Inc.
TIL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001789769
No open-market purchases or sales by Instil Bio, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $29.2M in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Instil Bio, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 30 | 31 | +1 |
| Shares | 3.94M | 4.25M | +311.2K (+7.9%) |
| Value | $30.0M | $45.9M | +$15.9M (+52.9%) |
New holders (5)
Institutions that held Instil Bio, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BML Capital Management, LLC | 348,735 | $3.77M | 2.52% |
| Barclays PLC | 479 | $5.17K | 0.00% |
| BNP Paribas Arbitrage, SA | 178 | $1.92K | 0.00% |
| Frazier Financial Advisors, LLC | 15 | $162 | 0.00% |
| Qube Research & Technologies Ltd | 1 | $11 | 0.00% |
Sold out (4)
Institutions that held Instil Bio, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Anson Funds Management LP | 17,344 | $132.2K |
| Royal Bank of Canada | 156 | $1.00K |
| Daiwa Securities Group Inc. | 18 | $0 |
| Covestor Ltd | 1 | $0 |